| 1/2 | US=39 / Câncer Bonavida B, Jazirehi AR, Vega MI, Huerta-Yepez S, Umezawa K, Suzuki E. Chemo-immunosensitization of resistant B-NHL as a result of rituximab (anti-CD20 mAb)-mediated inhibition of cell survival signaling pathaways. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 29-39. ISBN 978-1-58829-989-5. SENSIBILIZACAO IMUNITARIO; B-NHL; RITUXIMABE; ANTI-CD20 MAB; SINALIZACAO CELULAR |
| 2/2 | US=69 / Câncer Tsimberidou AM, Keating MJ. Targeted therapy in chronic lymphocytic leukemia. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 61-86. ISBN 978-1-60327-423-4. TERAPIA-ALVO EM LEUCEMIA LINFOCITICA CRONICA; CLL; PROGNOSTICO; TERAPIA; ALVO; FASE I; FLUDARABINA; ALEMTUZUMAB; RITUXIMAB; LENALIDOMIDA; TERAPIA GENETICA |